Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.80 |
| ▸ | HPGD | P15428 | 5/20 | 0.76 |
| ▸ | PDE4A | P27815 | 2/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.70 |
| ▸ | EEF2K | O00418 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.66 |
| ▸ | RAD52 | P43351 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5012465 | 0.83 | PDE4B (0.91) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL4047460 | 0.83 | PDE4B (1.00) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL4048347 | 0.82 | PDE4B (0.88) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL4045528 | 0.82 | PDE4B (0.94) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL4046997 | 0.81 | PDE4B (0.83) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL19805199 | 0.80 | EEF2K (0.77) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL5013091 | 0.80 | PDE4B (1.00) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL19805198 | 0.77 | KMT2A (0.96) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL4046180 | 0.77 | PDE4B (0.73) | KDM4EALDH1A1LMNANPSR1HIF1A | |
| SCHEMBL5245912 | 0.76 | PDE4B (0.79) | KDM4EALDH1A1LMNANPSR1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-08-27 | — | — | US | disclosed |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013096820-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | KDM4E 1255/4885ALDH1A1 3045/4885LMNA 4082/4885 |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | KDM4E 1255/4885ALDH1A1 3045/4885LMNA 4082/4885 |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | KDM4E 1255/4885ALDH1A1 3045/4885LMNA 4082/4885 |
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | KDM4E 1255/4885ALDH1A1 3045/4885LMNA 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.